Related content

Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20(+) non-Hodgkin’s lymphoma

By Dzietczenia Justyna   Wróbel Tomasz   Mazur Grzegorz   Poręba Rafał   Jaźwiec Bożena   Kuliczkowski Kazimierz  

Medical Oncology, Vol. 27, Iss. 3, 2010-09 ,pp. : 743-746

Humana Press, Inc

Access to resources Recommend Favorite

Lack of neuroprotection by an ACTH (4–9) analogue. A randomized trial in patients treated with vincristine for Hodgkin’s or non-Hodgkin’s lymphoma

By Koeppen S.   Verstappen C.   Körte R.   Scheulen M.   Strumberg D.   Postma T.   Heimans J.   Huijgens P.   Kiburg B.   Renzing-Köhler K.   Diener H.  

Journal of Cancer Research and Clinical Oncology, Vol. 130, Iss. 3, 2004-03 ,pp. : 153-160

Springer Publishing Company

Access to resources Recommend Favorite

Personal and Occupational Exposure to Organic Solvents and Risk of Non-Hodgkin’s Lymphoma (NHL) in Women (United States)

By Kato Ikuko  

Cancer Causes and Control, Vol. 16, Iss. 10, 2005-12 ,pp. : 1215-1224

Springer Publishing Company

Access to resources Recommend Favorite

Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin’s lymphoma

By Kilickap Saadettin   Yavuz Bunyamin   Aksoy Sercan   Sahiner Levent   Dincer Murat   Harputluoglu Hakan   Erman Mustafa   Aytemir Kudret   Tokgozoglu Lale   Barista Ibrahim  

Medical Oncology, Vol. 25, Iss. 4, 2008-12 ,pp. : 437-442

Humana Press, Inc

Access to resources Recommend Favorite

The comparison of spontaneous LDH release activity from cultured PBMC with sera LDH activity in non-Hodgkin’s lymphoma patients

By Jurišić V.   Konjević G.   Jančić-Nedeljkov R.   Sretenović M.   Banićević B.   Colović M.   Spužić I.  

Medical Oncology, Vol. 21, Iss. 2, 2004-06 ,pp. : 179-185

Humana Press, Inc

Access to resources Recommend Favorite